Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Craniopharyngioma × trametinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 76 Neoplasms 37 Carcinoma, Non-Small-Cell Lung 26 Colorectal Neoplasms 17 Neoplasm Metastasis 15 Multiple Myeloma 11 Glioma 11 Thyroid Neoplasms 10 Thyroid Carcinoma, Anaplastic 9 Pancreatic Neoplasms 9 Hematologic Neoplasms 8 Brain Neoplasms 8 Lung Neoplasms 6 Triple Negative Breast Neoplasms 5 Skin Neoplasms 5 Neurofibromatosis 1 5 Astrocytoma 5 Recurrence 4 Rectal Neoplasms 4 Lymphoma 4 Glioblastoma 4 Colonic Neoplasms 4 Cholangiocarcinoma 4 Breast Neoplasms 4 Uveal Melanoma 3 Oligodendroglioma 3 Neurofibroma, Plexiform 3 Leukemia, Myeloid, Acute 3 Biliary Tract Neoplasms 3 Bile Duct Neoplasms 3

Interventions

Surgical Procedures, Operative 3 Exenatide 3 tocilizumab 2 Temozolomide 2 Surveys and Questionnaires 2 Mental Status and Dementia Tests 2 Magnetic Resonance Spectroscopy 2 Donepezil 2 trametinib 1 tozuleristide 1 tovorafenib 1 temsirolimus 1 gallium Ga 68 dotatate 1 entinostat 1 dabrafenib 1 cobimetinib 1 carboxyamido-triazole 1 binimetinib 1 antineoplaston AS 2-1 1 antineoplaston A10 1 anlotinib 1 Verteporfin 1 Vemurafenib 1 Tumor Burden 1 Transurethral Resection of Bladder 1 Thalidomide 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy, Image-Guided 1 Radiotherapy, Conformal 1 Radiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05525273 2024-02-14

Swecranio

Skane University Hospital

Phase 2 Recruiting

Craniopharyngioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡